Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended December 2025, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2 billion, up 10.1% over the same period last year. EPS came in at $6.64, compared to $6.60 in the year-ago quarter.The reported revenue represents a surprise of +1.56% over the Zacks Consensus Estimate of $1.18 billion. With the consensus EPS estimate being $6.62, the EPS surprise was +0.27%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...